Because of CD38 roles in physiological T cell‐mediated immune responses against viral infections and reactivation,22 we sought to investigate the incidence of CMV reactivation and disease in MM patients treated with daratumumab‐based regimens as first‐ or second‐line therapy in a single‐center, two‐arm, real‐life experience. This evidence concerns the gene CD38 and Miyoshi myopathy.